Related Experiment Video
Updated: Jul 12, 2026
08:06
Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
Published on: November 10, 2016
Lead-guided prodrug development of small molecules as GLP-1R agonists
Hannah Lentschat1, Habiba G Aboelfotouh2, Peter Nabil2
1Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Bruederstr. 34, 04103 Leipzig, Germany.
Bioorganic Chemistry
|July 9, 2026
Summary
New ester analogs of danuglipron show promise for obesity and T2DM treatment. These compounds may offer sustained drug exposure and improved safety profiles compared to existing therapies.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Endocrinology
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists are key for obesity and type 2 diabetes mellitus (T2DM) treatment.
- Current GLP-1R therapies are primarily peptide-based, facing limitations like short duration and side effects.
- Danuglipron, a small-molecule GLP-1R agonist, showed efficacy but was discontinued due to safety and pharmacokinetic concerns.
Purpose of the Study:
- To design and synthesize novel acid and ester analogs of danuglipron.
- To evaluate the in vitro activity and pharmacokinetic potential of these new compounds.
- To explore prodrug strategies for improved GLP-1R agonist delivery.
Main Methods:
- Synthesis of danuglipron acid and ester analogs with diverse modifications.
- In vitro GLP-1R activity assays to assess compound efficacy.
- Mass spectrometry to confirm in vitro conversion of ester prodrugs to active metabolites in human plasma.
Main Results:
- Synthesized danuglipron analogs demonstrated comparable in vitro activity to existing treatments.
- Ester compound 4 showed controlled and sustained conversion to its active form (4a) in human plasma.
- These prodrugs suggest potential for modulated pharmacokinetic profiles.
Conclusions:
- Ester derivatives of danuglipron represent a potential strategy for developing improved GLP-1R agonists.
- Prodrugs may offer sustained systemic exposure and potentially enhanced safety.
- Further in vivo studies are required to validate pharmacokinetic and safety advantages.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.